Epilepsy Trial, Recruiting NCT06210022 Sponsor: IRCCS San Raffaele Condition: Epilepsy
Back to Epilepsy

Epilepsy Trial, Recruiting

NCT06210022
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For all participants:

  • People who are native Italian speakers with Italian as their only language
  • People aged between 18 and 60 years old
  • People with normal vision, or vision that is fully corrected with glasses or contact lenses
  • People who have given written and verbal agreement to take part in the study
  • People taking psychiatric medications (such as sleeping tablets, antipsychotics, or antidepressants) whose dose has remained unchanged for more than 4 weeks

For patients with drug-resistant epilepsy (DRE):

  • People diagnosed with a type of focal epilepsy where no clear cause has been found
  • People for whom at least 2 epilepsy medications have not worked at appropriate doses
  • People who have had at least 3 seizures in the last 2 months
  • People who have had a brain MRI scan taken within the last 5 years

For patients with well-controlled epilepsy (DSE):

  • People diagnosed with a type of focal epilepsy where no clear cause has been found, whose seizures are controlled after trying no more than 2 epilepsy medications
  • People who have been seizure-free for at least 6 months
  • People who have had a brain MRI scan taken within the last 5 years

For patients newly diagnosed with epilepsy (NDE):

  • People diagnosed with a type of focal epilepsy where no clear cause has been found within the last 3 months
  • People who have tried no more than 1 epilepsy medication
  • People who have had a brain MRI scan taken within the last 3 months

Who may not be able to join:

  • People over 60 years of age
  • People with a documented history of developmental delay
  • People whose brain scan shows specific abnormalities in brain structure, except for a condition called hippocampal sclerosis (a particular type of scarring in the brain)
  • People with a degenerative neurological condition (a condition causing progressive damage to the nervous system)
  • People with a history of other significant health conditions, including certain cancers diagnosed within the last 3 years, abnormal liver or kidney function, other neurological or psychiatric conditions, serious head injury, heart problems, or blood vessel problems in the brain
  • People with a history of alcohol or drug misuse

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +390226432154

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
IRCCS San Raffaele
Registry
ClinicalTrials.gov
Start date
20 June 2024
Est. completion
1 March 2027

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

To evaluate the prevalence of cognitive impairment in a population of focal cryptogenic epilepsy patients, comparing subjects diagnosed with DRE (drug resistant epilepsy) and subjects diagnosed with DSE (drug sensitive epilepsy);; To monitor the evolution of cognitive performance in DRE patients over a period of one year;; To evaluate whether seizure frequency constitute the main determinant of cognitive impairment;; To explore EEG-markers of DRE and DSE; To evaluate the entity of cognitive impairment in a population of focal cryptogenic epilepsy patients, comparing subjects diagnosed with DRE...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov